Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
03 juil. 2024 09h00 HE
|
Artelo Biosciences
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform
02 juil. 2024 09h00 HE
|
Artelo Biosciences
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02,...
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium
01 juil. 2024 09h00 HE
|
Artelo Biosciences
SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
04 juin 2024 08h30 HE
|
Artelo Biosciences
SOLANA BEACH, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
29 mai 2024 08h30 HE
|
Artelo Biosciences
SOLANA BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
13 mai 2024 08h00 HE
|
Artelo Biosciences
SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
10 mai 2024 09h00 HE
|
Artelo Biosciences
SOLANA BEACH, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
23 avr. 2024 08h30 HE
|
Artelo Biosciences
SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
22 avr. 2024 08h30 HE
|
Artelo Biosciences
SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
25 mars 2024 08h00 HE
|
Artelo Biosciences
SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...